Xue Bai

4.0k citations
87 papers · 3.1k indexed · 1 hit paper · h-index 29
Topics
MicroRNA in disease regulation (11 papers)RNA modifications and cancer (8 papers)Cancer-related molecular mechanisms research (8 papers)

In The Last Decade

Xue Bai

82 papers receiving 3.0k citations

Hit Papers

Nicotine promotes atherosclerosis via ROS-NLRP3-mediated ...20182026202020232018100200300400

Peers

Xue Bai
Comparison fields: 5 of 141
  • Molecular Biology 1.9k
  • Cancer Research 663
  • Immunology 468
  • Epidemiology 348
  • Cardiology and Cardiovascular Medicine 342
Replace Tingting Liu with:
Tingting Liu China
Jiyoung Park South Korea
Toshiyuki Sasaguri Japan
Pingjun Zhu China
Daisuke Yabe Japan
Yi Sun China
Concepción Peiró Spain
Amy Deik United States
Xue Bai relative to Tingting Liu China Tingting Liu's profile →
Citations per field
00.5×1.7×
Tingting Liu · 1×
Citations per year

Countries citing papers authored by Xue Bai

Since Specialization
Citations

This map shows the geographic impact of Xue Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue Bai more than expected).

Fields of papers citing papers by Xue Bai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue Bai. The network helps show where Xue Bai may publish in the future.

Co-authorship network of co-authors of Xue Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Xue Bai. A scholar is included among the top collaborators of Xue Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue Bai. Xue Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 0
4 2
5 1
6 0
7 13
8 2
9 59
10
Serum 14-3-3η Could Improve the Diagnostic Rate of Rheumatoid Arthritis and Correlates to Disease Activity.
16
11 4
12 42
13 3
14 130
15 25
16 32
17 18
18 60
19 37
20 44

About Xue Bai

Xue Bai is a scholar working on Cancer Research, Geriatrics and Gerontology and Molecular Biology, having authored 87 papers that have together received 3.1k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (11 papers), RNA modifications and cancer (8 papers) and Cancer-related molecular mechanisms research (8 papers). The work is most often cited by research in Cancer Research (663 citations), Molecular Biology (1.9k citations) and Immunology (468 citations). Xue Bai has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Baofeng Yang, Yong Zhang, Zhange Li, Chaoqian Xu, Xin Liu, Jiamin Li, Huan Yang, Xianxian Wu, Lin Yuan and Xiaohong Chen. Their work appears in journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Circulation Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026